FDA to Issue New Commissioner’s National Priority Vouchers to Companies Supporting U.S. National Interests | FDA

The .gov means it’s official.Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. FDA NEWS RELEASE More Press Announcements The U.S. Food and Drug Administration today announced its Commissioner’s National Priority Voucher (CNPV) program to enhance the health interests of Americans. The new voucher may be redeemed by drug developers to participate in a novel priority program by the FDA that shortens its review time from approximately 10-12 months to 1-2 months following a sponsor’s final drug application submission. The new CNPV process convenes experts from FDA offices for a team-based review rather than using the standard review system of a drug application being sent to numerous FDA offices. Clinical information will be reviewed by a

More Press Announcements For Immediate Release: June 17, 2025 The U.S. Food and Drug Administration today announced its Commissioner’s National Priority Voucher (CNPV) program to enhance the health interests of Americans. The new voucher may be redeemed by drug developers to participate in a novel priority program by the FDA that shortens its review time from approximately 10-12 months to 1-2 months following a sponsor’s final drug application submission. The new CNPV process convenes experts from FDA offices for a team-based review rather than using the standard review system of a drug applic

related reading

• Why the FDA Is Slow to Remove Drugspress.asimov.com
• Reputation (FDA’s Version)—Asteriskasteriskmag.com
• The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogatelfo.github.io
• The story of VaccinateCA - Works in Progress Magazineworksinprogress.co
• FDA Announces Major Steps to Implement Real-Time Clinical Trials | FDAfda.gov
• Who regulates the regulators?rootsofprogress.org
• Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher diseasesanofi.com
• Biotech’s Lost Archive | IFPifp.org
• Biotech’s Lost Archive | IFPifp.org
• What We Learned Doing Fast Grants | Futurefuture.a16z.com
• eCFR :: 7 CFR Chapter II Subchapter C -- Supplemental Nutrition Assistance and Food Distribution Programecfr.gov
• The Secret Gamble at the FDA That Exposed Americans to Risky Drugs — ProPublicapropublica.org